Michael Rosenzweig

Michael Rosenzweig, M.D., M.S., serves as Associate Professor and Chief of the Division of Multiple Myeloma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope. A board-certified hematologist-oncologist, he directs the amyloidosis program and specializes in plasma cell disorders including multiple myeloma, AL amyloidosis, Waldenstrom macroglobulinemia, and POEMS syndrome.

His educational background includes:

• B.A. in Psychology from Emory University (1989-1993)
• M.S. in Physiology and Biophysics (1993-1994)
• M.D. from University of Arizona College of Medicine (1997-2001)
• Internal Medicine Residency and Hematology/Oncology Fellowship at Boston Medical Center (2001-2009)
• Bone Marrow Transplantation Fellowship at Memorial Sloan Kettering Cancer Center (2009-2011)

Dr. Rosenzweig's research focuses on novel therapeutic strategies for plasma cell disorders, with particular emphasis on smoldering myeloma intervention and amyloidosis treatment optimization. He actively investigates drug repurposing (leflunomide), monoclonal antibodies (daratumumab), and CAR-T therapies targeting CS1 for light chain amyloidosis. His clinical work involves multidisciplinary collaboration with cardiology, nephrology, and neurology for comprehensive amyloidosis management.

His publication record demonstrates consistent focus on translational and clinical research in plasma cell malignancies, with recent work spanning from preclinical CAR-T studies to phase I/II trials of novel combinations for relapsed/refractory disease. Key themes include treatment sequencing, biomarker development, and addressing rare amyloid subtypes.

Scientific recognition includes:

• 2021 IDEA Grant for AL amyloidosis detection
• 2020 Pfizer grant for TTR amyloidosis management (Co-PI)
• 2018 Steven Gordon Innovation Grant
• 2015 David Seldin Research Grant
• 2013 ASBMT Clinical Research Scholar

As an educator, Dr. Rosenzweig mentors hematology-oncology fellows and leads clinical trials through industry partnerships and investigator-initiated grants. His current research portfolio emphasizes diagnostic pathway optimization and therapeutic strategies for precursor conditions. He practices at Duarte Cancer Center with active involvement in the plasma cell disease team and hematopoietic cell transplantation program.